PolyPid to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025
Rhea-AI Summary
PolyPid (Nasdaq: PYPD), a late-stage biopharma company focused on improving surgical outcomes, has announced its participation in the upcoming Lytham Partners Spring 2025 Investor Conference. The virtual event will take place on May 29, 2025.
The company will deliver a webcast presentation at 10:15 a.m. ET and conduct one-on-one meetings with investors throughout the event. The presentation will be accessible through the conference website and will be available for replay after the event.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, PYPD gained 3.20%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
PETACH TIKVA, Israel, May 20, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2025 Investor Conference, taking place virtually on Thursday, May 29, 2025.
Company Webcast
The webcast presentation will take place at 10:15 a.m. ET on Thursday, May 29, 2025. The webcast can be accessed by visiting the conference home page at https://lythampartners.com/spring2025/ or directly at https://app.webinar.net/QyL1ZkGZK8z. The webcast will also be available for replay following the event.
1x1 Meetings
Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at 1x1@lythampartners.com or register for the event at https://lythampartners.com/spring2025invreg/.
About PolyPid
PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX100 is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginning with glioblastoma.
For additional Company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn.
Contacts:
PolyPid Ltd.
Ori Warshavsky
COO – US
908-858-5995
IR@Polypid.com
Investors:
Brian Ritchie
LifeSci Advisors
212-915-2578
britchie@lifesciadvisors.com
FAQ
When is PolyPid (PYPD) presenting at the Lytham Partners Spring 2025 Conference?
How can investors access PolyPid's (PYPD) presentation at the Lytham Partners Conference?
How can investors arrange one-on-one meetings with PolyPid (PYPD) management?
What is PolyPid's (PYPD) main business focus?
